Xibornol
Chemical compound
- J01XX02 (WHO)
- 4,5-dimethyl-2-[(1S,4R,6R)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl]phenol
- 13741-18-9
Y
- 11777299
- DB13714
Y
- 9951982
Y
- RQ12GMY0FZ
- D07433
Y
- CHEBI:131713
Y
- ChEMBL2104519
- DTXSID60472406
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- Oc1cc(c(cc1C2CC3CCC2(C)C3(C)C)C)C
InChI
- InChI=1S/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3
Y
- Key:RNRHMQWZFJXKLZ-UHFFFAOYSA-N
Y
Xibornol is a lipophilic substance with antiseptic properties, mainly used in Italy and Spain. It is primarily administered to the throat as a spray mouthwash. As of 2007, all approved forms are water-based suspensions.[1]
The drug was discovered in the 1970s.[2]
References
- ^ Cirri M, Mura P, Mora PC (August 2007). "Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems". International Journal of Pharmaceutics. 340 (1–2): 84–91. doi:10.1016/j.ijpharm.2007.03.021. PMID 17531411.
- ^ Celandroni F, Mazzantini D, Calvigioni M, Ceccanti S, Vecchiani S, Battaglia S, et al. (2022). "Antimicrobial Activity of Xibornol and a Xibornol-Based Formulation Against Gram-Positive Pathogens of the Respiratory Tract". Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology. Vol. 1369. pp. 101–106. doi:10.1007/5584_2021_664. hdl:11568/1115592. ISBN 978-3-031-01994-4. PMID 34387849. S2CID 236998271.
- v
- t
- e
Lipoglycopeptides
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e